Physician profile
Arvind Gopal
NPI 1346382082
$2,156.91
in general payments reported to CMS, 2019-2025
16 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,507 · 2020: $11.68 · 2021: $271 · 2022: $169 · 2023: $75.12 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $198.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $1,351.53 | 2019 | |
| Abbvie INC. | $270.32 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $123.03 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $103.21 | 2019-2020 | |
| Ucb, INC. | $58.05 | 2021-2022 | |
| Gilead Sciences, INC. | $42.35 | 2019-2021 | |
| Celgene Corporation | $39.99 | 2021-2023 | Zeposia |
| Alnylam Pharmaceuticals INC. | $36.84 | 2021 | |
| Braintree Laboratories, INC. | $19.38 | 2021 | |
| Intercept Pharmaceuticals, INC. | $19.15 | 2021 | |
| Redhill Biopharma INC. | $19.14 | 2021 | |
| Medtronic, INC. | $18.44 | 2021 | |
| Organon LLC | $17.17 | 2023 | Hadlima |
| Janssen Biotech, INC. | $13.74 | 2019 | |
| Dova Pharmaceuticals | $12.62 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Gopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.